bioAffinity Technologies Presents Scientific Discoveries Advancing Cancer Therapeutics and Diagnostics at Two Global Conferences

PUBLISHED ON June 23, 2021

June 23, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, will present the Company’s discoveries in the field of cancer diagnostics and therapeutics at the RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium June 23 – 25, 2021, and the International Conference on Porphyrins and Phthalocyanines (ICPP) June 28 – July 3, 2021.

read more

Leading Cell Biology Journal Publishes bioAffinity Technologies’ Groundbreaking Research on Porphyrins

PUBLISHED ON March 3, 2021

March 3, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced that a scientific paper that explains how porphyrins are selectively incorporated into cancer cells has been published in the Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal).

read more

SA biotech pursuing deal to access $5B China market

PUBLISHED ON February 11, 2021

San Antonio Business Journal (February 8, 2021) “China represents a $5 billion market for CyPath© Lung. An estimated 780,000 people will be diagnosed annually in China with lung cancer, most often at late stage,” bioAffinity President and CEO Maria Zannes said. "Fosun Long March is a driving force in health care, bringing medical breakthroughs to China and the world that improve the health and clinical outcomes of patients.”

read more

bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.